Monocyte aryl hydrocarbon hydroxylase (AHH) activity mimics Kupffer cell and hepatocyte AHH activity in an animal model of liver disease

1991 ◽  
Vol 69 (12) ◽  
pp. 1797-1803 ◽  
Author(s):  
T. C. Peterson ◽  
C. N. Williams ◽  
D. A. Malatjalian

We have previously reported that monocyte aryl hydrocarbon hydroxylase (AHH) activity is depressed in patients with liver disease and is decreased more in cirrhosis than in early stage liver disease. To determine if monocyte AHH activity reflects liver AHH activity, we studied an animal model of cirrhosis, i.e., yellow phosphorus induced cirrhosis in the pig. AHH activity was detectable in monocytes isolated from peripheral blood of normal pigs (0.32 ± 0.13 nmol∙mg−1 P∙h−1, n = 11) and was comparable to the level of AHH activity in hepatic Kupffer cells isolated from wedge or needle biopsies of livers of normal pigs (0.38 ± 0.21, n = 7). The AHH level in pig Kupffer cells was approximately 10% of the AHH level in hepatocytes and microsomes. To induce liver disease, pigs were administered yellow phosphorus (0.6 mg/kg) 5 days per week for 16 weeks. At 4 weeks of treatment, monocyte AHH activity was not different from control and liver histology was normal. Depression of monocyte AHH activity was evident at 8 weeks of treatment when liver fibrosis was seen histologically. At 12 weeks of treatment when histology revealed extensive liver fibrosis and collagen levels were elevated, the level of monocyte AHH activity was decreased 67% compared with controls. Similar changes were observed at 12 weeks in Kupffer cell AHH activity (86% decrease) and hepatocyte AHH activity (70% decrease) compared with controls. These results suggest that monocyte AHH activity reflects liver AHH activity and may be a good indicator of change in liver enzyme function in liver disease in the pig model of cirrhosis.Key words: aryl hydrocarbon hydroxylase, animal model of liver disease, monocyte, hepatocyte, Kupffer cells.

2021 ◽  
Vol 116 (1) ◽  
pp. S519-S520
Author(s):  
Shilpa Junna ◽  
Malini Chauhan ◽  
Michael Bonelli ◽  
Zachary Warner ◽  
Mark Borgstrom ◽  
...  

2022 ◽  
Author(s):  
Keqin Ji ◽  
Mingrui Fan ◽  
Dong Huang ◽  
Lingna Sun ◽  
Bingqin Li ◽  
...  

CLD/NIN@LIEV decreases the nonspecific phagocytosis of nanoparticles and suppresses the inflammatory cytokines secreted by Kupffer cells, thus enhancing the therapeutic effects against liver fibrosis.


Hepatology ◽  
2013 ◽  
Vol 59 (1) ◽  
pp. 130-142 ◽  
Author(s):  
Jinghong Wan ◽  
Merieme Benkdane ◽  
Fatima Teixeira-Clerc ◽  
Stéphanie Bonnafous ◽  
Alexandre Louvet ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Yu-long Bao ◽  
Li Wang ◽  
Hai-ting Pan ◽  
Tai-ran Zhang ◽  
Ya-hong Chen ◽  
...  

Liver fibrosis refers to the process underlying the development of chronic liver diseases, wherein liver cells are repeatedly destroyed and regenerated, which leads to an excessive deposition and abnormal distribution of the extracellular matrix such as collagen, glycoprotein and proteoglycan in the liver. Liver fibrosis thus constitutes the pathological repair response of the liver to chronic injury. Hepatic fibrosis is a key step in the progression of chronic liver disease to cirrhosis and an important factor affecting the prognosis of chronic liver disease. Further development of liver fibrosis may lead to structural disorders of the liver, nodular regeneration of hepatocytes and the formation of cirrhosis. Hepatic fibrosis is histologically reversible if treated aggressively during this period, but when fibrosis progresses to the stage of cirrhosis, reversal is very difficult, resulting in a poor prognosis. There are many causes of liver fibrosis, including liver injury caused by drugs, viral hepatitis, alcoholic liver, fatty liver and autoimmune disease. The mechanism underlying hepatic fibrosis differs among etiologies. The establishment of an appropriate animal model of liver fibrosis is not only an important basis for the in-depth study of the pathogenesis of liver fibrosis but also an important means for clinical experts to select drugs for the prevention and treatment of liver fibrosis. The present study focused on the modeling methods and fibrosis characteristics of different animal models of liver fibrosis, such as a chemical-induced liver fibrosis model, autoimmune liver fibrosis model, cholestatic liver fibrosis model, alcoholic liver fibrosis model and non-alcoholic liver fibrosis model. In addition, we also summarize the research and application prospects concerning new organoids in liver fibrosis models proposed in recent years. A suitable animal model of liver fibrosis and organoid fibrosis model that closely resemble the physiological state of the human body will provide bases for the in-depth study of the pathogenesis of liver fibrosis and the development of therapeutic drugs.


Sign in / Sign up

Export Citation Format

Share Document